SAB Biotherapeutics Inc (SABS) — Capital Reinvestment Ratio
Latest as of December 2022:
0.54x
SAB Biotherapeutics Inc (SABS) has a Capital Reinvestment Ratio of 0.54x as of December 2022, meaning it reinvests 1% of its operating cash flow ($216.72K) in capital expenditures ($117.75K). See SABS free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.54x
Capex / Operating Cash Flow
Operating Cash Flow
$216.72K
USD
Capital Expenditures
$117.75K
USD
Data as of
Dec 2022
Most recent filing
SAB Biotherapeutics Inc Capital Reinvestment Ratio (2020–2021)
This chart tracks SAB Biotherapeutics Inc's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for SAB Biotherapeutics Inc (2020–2021)
Year-by-year Capital Reinvestment Ratio for SAB Biotherapeutics Inc from 2020 to 2021. For live market cap and broader valuation context, see SABS market cap.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 5.51x | $1.99 Million | $10.94 Million | ▲ +332.8% |
| 2020 | 1.27x | $10.00 Million | $12.73 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow